Literature DB >> 2454869

Constitutive expression of c-fos antisense RNA blocks c-fos gene induction by interferon and by phorbol ester and reduces c-myc expression in F9 embryonal carcinoma cells.

B Z Levi1, K Ozato.   

Abstract

To address the role of c-fos proto-oncogene we constructed a plasmid that allows constitutive expression of RNA complementary to c-fos mRNA, and stably introduced this plasmid into F9 embryonal carcinoma cells. Some F9 clones expressing c-fos antisense RNA had a reduced basal level of c-fos mRNA, and were unable to induce a c-fos mRNA as well as its protein when stimulated with phorbol ester or with interferon (IFN). Nevertheless, the ability to induce major histocompatibility class I genes following IFN treatment was not impaired in these clones. Clones expressing c-fos antisense RNA grew as rapidly as control F9 cells, and underwent differentiation after retinoic acid treatment. Unexpectedly, constitutive expression of c-myc mRNA was reduced on average by 10-fold in clones expressing c-fos antisense RNA. However, expression of the p53 gene and heat shock gene hsp 70 was not affected in these clones, indicating the existence of a specific regulatory linkage between c-fos and c-myc genes. Cycloheximide treatment led to induction of a large amount of c-fos mRNA in clones expressing c-fos antisense RNA as well as in control F9 clones. The amount of c-fos antisense RNA was also increased by cycloheximide treatment. We postulate that c-fos antisense RNA blocks expression of the endogenous c-fos gene by accelerating the degradation of c-fos mRNA and that cycloheximide treatment interferes with this degradation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2454869     DOI: 10.1101/gad.2.5.554

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  8 in total

1.  Transcription of a subset of human class II major histocompatibility complex genes is regulated by a nucleoprotein complex that contains c-fos or an antigenically related protein.

Authors:  S J Ono; V Bazil; B Z Levi; K Ozato; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

2.  c-Fos activated phospholipid synthesis is required for neurite elongation in differentiating PC12 cells.

Authors:  Germán A Gil; Daniela F Bussolino; Maximiliano M Portal; Adolfo Alfonso Pecchio; Marianne L Renner; Graciela A Borioli; Mario E Guido; Beatriz L Caputto
Journal:  Mol Biol Cell       Date:  2004-02-06       Impact factor: 4.138

3.  Suppression of postischemic hippocampal nerve growth factor expression by a c-fos antisense oligodeoxynucleotide.

Authors:  J K Cui; C Y Hsu; P K Liu
Journal:  J Neurosci       Date:  1999-02-15       Impact factor: 6.167

4.  Neonatal induction of a nuclear protein that binds to the c-fos enhancer.

Authors:  B Z Levi; J W Kasik; P A Burke; R Prywes; R G Roeder; E Appella; K Ozato
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

5.  Suppression of ischemia-induced fos expression and AP-1 activity by an antisense oligodeoxynucleotide to c-fos mRNA.

Authors:  P K Liu; A Salminen; Y Y He; M H Jiang; J J Xue; J S Liu; C Y Hsu
Journal:  Ann Neurol       Date:  1994-10       Impact factor: 10.422

6.  Difference in transcriptional regulatory function between c-Fos and Fra-2.

Authors:  T Suzuki; H Okuno; T Yoshida; T Endo; H Nishina; H Iba
Journal:  Nucleic Acids Res       Date:  1991-10-25       Impact factor: 16.971

7.  Retinoic acid-dependent transactivation of major histocompatibility complex class I promoters by the nuclear hormone receptor H-2RIIBP in undifferentiated embryonal carcinoma cells.

Authors:  T Nagata; J H Segars; B Z Levi; K Ozato
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-01       Impact factor: 11.205

8.  JunD mutants with spontaneously acquired transforming potential have enhanced transactivating activity in combination with Fra-2.

Authors:  T Kameda; A Akahori; M H Sonobe; T Suzuki; T Endo; H Iba
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.